The High Court of Australia has effectively closed the door on the patentability of AI-generated inventions, at least for the moment.
By refusing to hear an appeal in the high-profile "DABUS" case, the Court has left the Full Federal Court's previous ruling in place: under current Australian law, an inventor must be a human being.
This decision marks the end of a specific legal campaign by Dr Stephen Thaler to have his AI system, DABUS, recognised as the sole inventor of a patent. For business leaders, particularly in research and development (R&D)-intensive sectors like pharmaceuticals and tech, this confirms that purely AI-generated innovations remain unpatentable assets in Australia.
Key takeaways
Humans only: An AI model cannot be named as an inventor for an Australian patent application.
Procedural roadblock: The High Court refused the appeal not necessarily on the philosophical merits of AI creativity, but because this specific case was "not the appropriate vehicle" to test the law.
R&D Risk: Companies relying heavily on AI for discovery and design must ensure human contribution is sufficient to claim inventorship, or risk holding unpatentable technology.
Why the High Court of Australia said "No"
The refusal to grant special leave to appeal was driven by procedure rather than a rejection of AI's potential.
The High Court (Justices Gordon, Edelman, and Gleeson) determined that Dr Thaler’s application was flawed from the start. The Patent Office had originally rejected the application at the "formalities" stage, a preliminary check, rather than during a substantive examination of who actually invented the technology.
Crucially, the case was built on an agreed premise: Dr Thaler had explicitly stated that he was not the inventor, and that the AI was the sole creator. The Court found that hearing the appeal would prevent them from exploring a critical alternative reality: whether Dr Thaler, as the owner and operator of the AI, could have been considered the inventor despite the AI's involvement.
Because the case was framed so narrowly, the Court decided it was the wrong opportunity to settle such a significant point of law.
The commercial reality for R&D
For now, the legal status quo remains. This has immediate ramifications for industries that use machine learning to accelerate innovation.
If your R&D process involves an AI model identifying a new drug molecule or optimising an engineering design without significant human intervention, you face a dilemma. You cannot name the AI as the inventor, and if you name a human who didn't actually contribute to the inventive step, the patent could be invalid.
Strategic impact: Innovation leaders must ensure their R&D workflows document human intellectual contribution. To secure patent protection in Australia, you need a human "inventor" who can legitimately claim to have contributed to the creative concept, even if AI did the heavy lifting.
What's Next? Global fragmentation
While the door is shut in Australia, the issue is not dead globally. Dr Thaler’s campaign is testing legal systems worldwide.
Unlike Australia, the case has proceeded to the highest level in the United Kingdom, with the UK Supreme Court set to hear arguments on whether the Patents Act 1977 (UK) can accommodate non-human inventors.
Until legislative reform occurs or a new test case arises with different facts, Australian businesses must operate on the principle that IP rights are a strictly human privilege.
Which stakeholders are impacted":
